期刊
CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY
卷 16, 期 4, 页码 304-307出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MED.0b013e32832d88e4
关键词
acromegaly; growth hormone receptor antagonist; lanreotide; octreotide; pegvisomant; radiosurgery; somatostatin receptor analogs; transphenoidal surgery
Purpose of review Description of recent outcomes and approaches to the treatment of patients with de-novo and recurrent acromegaly. Recent findings Radiosurgery for acromegaly results in a higher likelihood of remission and an earlier time to remission than does conventional radiotherapy. Somatostatin analogs results in control of acromegaly and one half of patients. Combining treatment with pegvisomant and somatostatin analogs results in overall improved quality of life. Summary Existing treatments offer patients and their treating physicians opportunities to restore life expectancy to normal and reverse many of the symptoms and signs of acromegaly.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据